Anika Therapeutics (ANIK) EBIAT: 2010-2025
Historic EBIAT for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -$3.2 million.
- Anika Therapeutics' EBIAT rose 89.39% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year increase of 65.43%. This contributed to the annual value of -$56.4 million for FY2024, which is 31.79% up from last year.
- Anika Therapeutics' EBIAT amounted to -$3.2 million in Q3 2025, which was up 31.68% from -$4.6 million recorded in Q2 2025.
- Over the past 5 years, Anika Therapeutics' EBIAT peaked at $6.5 million during Q2 2021, and registered a low of -$63.0 million during Q4 2023.
- Its 3-year average for EBIAT is -$14.0 million, with a median of -$4.9 million in 2025.
- In the last 5 years, Anika Therapeutics' EBIAT spiked by 184.73% in 2021 and then crashed by 1,183.62% in 2023.
- Quarterly analysis of 5 years shows Anika Therapeutics' EBIAT stood at -$5.8 million in 2021, then grew by 15.28% to -$4.9 million in 2022, then slumped by 1,183.62% to -$63.0 million in 2023, then surged by 65.29% to -$21.9 million in 2024, then skyrocketed by 89.39% to -$3.2 million in 2025.
- Its EBIAT stands at -$3.2 million for Q3 2025, versus -$4.6 million for Q2 2025 and -$4.9 million for Q1 2025.